ArticleJournal of virology2002
Inhibition of tumor necrosis factor alpha-induced NF-kappa B activation by the adenovirus E3-10.4/14.5K complex.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Nonclinical characterization of ICVB-1042 as a selective oncolytic adenovirus for solid tumor treatment.Communications biology · 2024Article
- Orf Virus ORF120 Protein Positively Regulates the NF-κB Pathway by Interacting with G3BP1.Journal of virology · 2021Article
- Article
- Transcriptomic and proteomic analyses reveal new insights into the regulation of immune pathways during adenovirus type 2 infection.BMC microbiology · 2019Article
- Evidence for the Involvement of the Master Transcription Factor NF-κB in Cancer Initiation and Progression.Biomedicines · 2018Review
- Human Adenoviruses, Cholesterol Trafficking, and NF-κB Signaling.Journal of immunological sciences · 2018Article
- Mechanisms of pathogenesis of emerging adenoviruses.F1000Research · 2017Review
- Article
- Homologous recombination in E3 genes of human adenovirus species D.Journal of virology · 2013Article
- A novel hybrid adenoretroviral vector with more extensive E3 deletion extends transgene expression in submandibular glands.Human gene therapy methods · 2012Article
- Modulation of NF-κB signalling by microbial pathogens.Nature reviews. Microbiology · 2011Review
- Specific NFkappaB subunit activation and kinetics of cytokine induction in adenoviral keratitis.Molecular vision · 2009Article
- Cowpox virus expresses a novel ankyrin repeat NF-kappaB inhibitor that controls inflammatory cell influx into virus-infected tissues and is critical for virus pathogenesis.Journal of virology · 2009Article
- Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic beta-cells to correct diabetes in allogeneic mice.Gene therapy · 2009Article
- Gene therapy that inhibits NF-kappaB results in apoptosis of human hepatocarcinoma by recombinant adenovirus.World journal of gastroenterology · 2006Article
- Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death.Journal of virology · 2006Article
- Article
- Mechanism for removal of tumor necrosis factor receptor 1 from the cell surface by the adenovirus RIDalpha/beta complex.Journal of virology · 2005Article
- Adenovirus early region 3 transgenes expressed in beta cells prevent autoimmune diabetes in nonobese diabetic mice: effects of deleting the adenovirus death protein 11.6K.Journal of virology · 2005Article
- Inhibition of tumor necrosis factor (TNF) signal transduction by the adenovirus group C RID complex involves downregulation of surface levels of TNF receptor 1.Journal of virology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Recombinant adenoviruses (Ads) are useful tools in gene transfer because they are able to infect a wide variety of tissues and cell types and do not require a replicating target cell. However, transgene expression is only transient due to host innate and acquired immune responses to the virus. Most recombinant Ads have deletions of early region 3 (E3) genes, allowing more space for insertion of the transgene. Although the E3 region is not necessary for infection, it has been observed that these "nonessential" genes have immunomodulatory properties. We demonstrate here that the E3 region of Ad inhibits the activation of NF-kappa B induced by tumor necrosis factor alpha (TNF-alpha) and interleukin-1. Ad E3 is able to prevent NF-kappa B from entering the nucleus, where it is normally active. Ad E3 also appears to function by preventing the activation of the kinase complex, IKK, which is responsible for phosphorylation of I kappa B that retains NF-kappa B in the cytoplasm in an inactive state. The prevention of NF-kappa B activation has been mapped to a complex of two of the seven E3 products, E3-10.4K and E3-14.5K (RID alpha/beta). These and other studies indicate that, by using Ad vectors containing the E3 region, it may be possible to reduce the harmful proinflammatory effects of TNF-alpha and other cytokines that compromise the use of Ad gene therapy vectors in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.